PubMed ID: 37656913
Author(s): Dallalzadeh LO, Ting M, Topilow N, Robbins SL, Liu CY, Burkat CN, Korn BS, Kikkawa DO. Teprotumumab-related Cutaneous Hypersensitivity Reactions. Ophthalmic Plast Reconstr Surg. 2023 Sep 1. doi: 10.1097/IOP.0000000000002482. Online ahead of print. PMID 37656913
Journal: Ophthalmic Plastic And Reconstructive Surgery, Sep 2023
The authors report 4 cases of cutaneous hypersensitivity reactions developing in the course of teprotumumab treatment for thyroid eye disease. The onset of the cutaneous hypersensitivity reaction was also observed during the treatment course in all cases, between the second and fifth infusions. Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment.
Copyright © 2023 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.